General Dermatology

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Verrica Pharmaceuticals initiates phase 3 trials for VP-102, aiming to provide an effective treatment for common warts, addressing significant unmet needs.

Johnson & Johnson's nipocalimab shows promise in reducing systemic lupus erythematosus activity, paving the way for a phase 3 development program.

This review of the latest dermatologic studies includes insights on dupilumab-associated rosacea, the prevalence of young adult acne, psoriasis patients with acute coronary syndrome, and more.

Chronic skin diseases like psoriasis and AD are linked to high smoking and other addiction rates, highlighting the need for integrated psychosocial support.

Explore the latest findings on GLP-1 RA injection-site and dermatologic reactions, enhancing treatment adherence and patient counseling strategies.

Mabwell’s investigational 9MW3811 is the first IL-11–targeting therapy to enter clinical evaluation for pathological scarring.

Explore the latest insights on hyperhidrosis, its impact on quality of life, and advancements in effective treatment options for this often-overlooked condition.

Discover essential dermatology awareness dates and initiatives for 2026, as we enhance patient care with updates, interviews, and resources throughout the year.

Share your thoughts and help shape our content by telling us what topics you want to see more of this year.

Explore the top headlines of 2025, including insights on the latest clinical trials, therapeutic updates, and more.

Innovative approaches in 2025 have enhanced skin health equity by improving global access to dermatology trials, ensuring diverse representation, and community engagement.

Discover groundbreaking FDA dermatology approvals in 2025, featuring innovative therapies for chronic skin conditions and pediatric care advancements.

Dermatology evolves in 2025, focusing on personalized care, safety, and technology integration, while addressing systemic health and patient outcomes.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

John Barbieri, MD, MBA; Ted Rosen, MD; Peter Lio, MD; Shanna Miranti, MPAS, PA-C; and Larissa Schmidt, DPM, share what gifts they would give to the field of dermatology this holiday season.

Hilary Baldwin, MD; Douglas DiRuggiero, DMSc, MHS, PA-C; Diego Ruiz DaSilva, MD; Ken Korber, PA-C; Patrick Burnett, MD, PhD; and Lisa Weiss, PA-C, share what gifts they would give to the field of dermatology this holiday season.

Explore our top performing social media posts of 2025, including insights on the latest clinical trials, FDA approvals, and more.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

In case you missed it, this week we had news on phase 3 data for zasocitinib in psoriasis, wildfire air pollution's impact on AD clinic visits, the FDA's clearance of REX-8756's IND application, and more.

Discover effective treatment strategies for keloids and hypertrophic scars in skin of color, emphasizing personalized approaches and combination therapies.

Energy and protein drinks may exacerbate acne through high sugar and insulin levels, impacting skin health among athletes and students.

What were the top dermatology hits of 2025?